• Explore /
  • Poster
  • / Efficacy and safety of futibatinib for refractory advanced solid malignancies with <em>FGFR</em> alterations identified in circulating tumor DNA: TiFFANY, A GOZILA-affiliated Trial.

Efficacy and safety of futibatinib for refractory advanced solid malignancies with FGFR alterations identified in circulating tumor DNA: TiFFANY, A GOZILA-affiliated Trial.

Abstract Poster

Authors

null

Tomoko Jogo

Department of Surgery, Munakata Medical Association Hospital, Munakata, Japan

Tomoko Jogo , Eiji Shinozaki , Toshiki Masuishi , Takeshi Kato , Tomohiro Nishina , Taito Esaki , Yoshito Komatsu , Ken Kato , Mitsuko Suzuki , Nozomu Fuse , Akihiro Sato , Takashi Ikeno , Shogo Nomura , Hideaki Bando , Justin Iver Odegaard , Satoshi Fujii , Hiromichi Ebi , Takayuki Yoshino , Yoshiaki Nakamura

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Small Molecules

Clinical Trial Registration Number

JapicCTI-194624

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 3102)

DOI

10.1200/JCO.2023.41.16_suppl.3102

Abstract #

3102

Poster Bd #

300

Abstract Disclosures

Similar Posters

First Author: Tomoko Jogo

First Author: Hiroya Taniguchi

First Author: Kaysia Ludford

First Author: Panpan Zhang